Advertisement

Outcome of ketogenic diets in GLUT1 deficiency syndrome in Japan: A nationwide survey

Published:February 25, 2016DOI:https://doi.org/10.1016/j.braindev.2016.01.002

      Abstract

      Objectives

      To evaluate the outcome of ketogenic diets (KDs) in patients with glucose transport type 1 deficiency syndrome (GLUT1DS) in Japan.

      Methods

      A nationwide survey for GLUT1DS was conducted by sending questionnaires to board-certified pediatric neurologists nationwide to obtain clinical and laboratory data.

      Results

      Among 39 patients whose diagnosis was confirmed molecularly or by the 3-O-methylglucose uptake assay, 31 were treated with KDs for longer than 1 month. Seventeen patients (55%) were on the modified Atkins diet, 11 (35%) were on the classic KD, and 3 were on the medium-chain triglyceride (MCT) diet. The median values and ranges of serum β-hydroxybutyrate levels in patients on the modified Atkins diet, classic KD and MCT diet were 2.5 mM (0.75–4.1), 1.7 mM (0.23–3.5) and 2.6 mM (1.5–3.0), respectively. The KDs were effective on seizures (80%), aggravation after fasting (80%) and ataxia (79%). Thus, ataxia was as responsive as seizures. Two patients on the classic KD with a ketogenic ratio as low as 1:1 showed improvement in neurological symptoms. The development or intelligence quotient measured using the same psychological scales before and after the KDs in 9 patients did not show a significant improvement; the median quotients before and after the diets were 40 (12–91) and 46 (12–67).

      Conclusion

      The KDs were most effective on seizures, transient aggravation after fasting and ataxia. The efficacy on intellectual development was equivocal. The modified Atkins diet was more commonly used for GLUT1DS in this study, and its ketogenicity was equivalent to the classic KD.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • De Vivo D.C.
        • Trifiletti R.R.
        • Jacobson R.I.
        • Ronen G.M.
        • Behmand R.A.
        • Harik S.I.
        Defective glucose transport across the blood–brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay.
        N Engl J Med. 1991; 325: 703-709
        • Klepper J.
        • Leiendecker B.
        GLUT1 deficiency syndrome – 2007 update.
        Dev Med Child Neurol. 2007; 49: 707-716
        • De Vivo D.C.
        • Leary L.
        • Wang D.
        Glucose transporter 1 deficiency syndrome and other glycolytic defects.
        J Child Neurol. 2002; 17 (3S15–23 [discussion 3S24–5])
        • Suls A.
        • Mullen S.A.
        • Weber Y.G.
        • Verhaert K.
        • Ceulemans B.
        • Guerrini R.
        • et al.
        Early-onset absence epilepsy caused by mutations in the glucose transporter GLUT1.
        Ann Neurol. 2009; 66: 415-419
        • Klepper J.
        GLUT1 deficiency syndrome in clinical practice.
        Epilepsy Res. 2012; 100: 272-277
        • Ito S.
        • Oguni H.
        • Ito Y.
        • Ishigaki K.
        • Ohinata J.
        • Osawa M.
        Modified Atkins diet therapy for a case with glucose transporter type 1 deficiency syndrome.
        Brain Dev. 2008; 30: 226-228
        • Pascual J.M.
        • Liu P.
        • Mao D.
        • Kelly D.I.
        • Hernandez A.
        • Sheng M.
        • et al.
        Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement.
        JAMA Neurol. 2014; 71: 1255-1265
        • Brockmann K.
        The expanding phenotype of GLUT1-deficiency syndrome.
        Brain Dev. 2009; 31: 545-552
        • De Giorgis V.
        • Veggiotti P.
        GLUT1 deficiency syndrome 2013: current state of the art.
        Seizure. 2013; 22: 803-811
        • Ito Y.
        • Takahashi S.
        • Kagitani-Shimono K.
        • Natsume J.
        • Yanagihara K.
        • Fujii T.
        • et al.
        Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan.
        Brain Dev. 2015; 37: 780-789
        • Leen W.G.
        • Klepper J.
        • Verbeek M.M.
        • Leferink M.
        • Hofste T.
        • van Engelen B.G.
        • et al.
        Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder.
        Brain. 2010; 133: 655-670
        • Klepper J.
        Glucose transporter deficiency syndrome (GLUT1DS) and the ketogenic diet.
        Epilepsia. 2008; 49: 46-49
        • Ito Y.
        • Oguni H.
        • Ito S.
        • Oguni M.
        • Osawa M.
        A modified Atkins diet is promising as a treatment for glucose transporter type 1 deficiency syndrome.
        Dev Med Child Neurol. 2011; 53: 658-663